2021-03-17T12:40:49Z
2021-03-17T12:40:49Z
2021-02-03
2021-03-17T12:40:49Z
Methyl-CpG binding protein 2 (MeCP2) is a transcriptional regulator and a chromatin-associated structural protein. MeCP2 deregulation results in two neurodevelopmental disorders: MeCP2 dysfunction is associated with Rett syndrome, while excess of activity is associated with MeCP2 duplication syndrome. MeCP2 is an intrinsically disordered protein (IDP) constituted by six structural domains with variable, small percentage of well-defined secondary structure. Two domains, methyl-CpG binding domain (MBD) and transcription repressor domain (TRD), are the elements responsible for dsDNA binding ability and recruitment of the gene transcription/silencing machinery, respectively. Previously we studied the influence of the completely disordered, MBD-flanking domains (N-terminal domain, NTD, and intervening domain, ID) on the structural and functional features of the MBD (Claveria-Gimeno, R. et al. Sci Rep. 2017, 7, 41,635). Here we report the biophysical study of the influence of the remaining domains (transcriptional repressor domain, TRD, and C-terminal domains, CTDα and CTDβ) on the structural stability of MBD and the dsDNA binding capabilities of MBD and ID. The influence of distant disordered domains on MBD properties makes it necessary to consider the NTD-MBD-ID variant as the minimal protein construct for studying dsDNA/chromatin binding properties, while the full-length protein should be considered for transcriptional regulation studies.
Article
Accepted version
Published version
English
Síndrome de Rett; Proteïnes recombinants; Cromatina; Rett syndrome; Recombinant proteins; Chromatin
Elsevier B.V.
Reproducció del document publicat a: https://doi.org/10.1016/j.ijbiomac.2021.01.206
International Journal of Biological Macromolecules, 2021, vol. 175, p. 58-66
https://doi.org/10.1016/j.ijbiomac.2021.01.206
cc-by-nc-nd (c) Ortega Alarcón et. al., 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/